(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 4. In vitro binding of LAG-1/CSL and ELT-2/GATA to enhA
sequences. (A) Electrophoretic mobility shift assay (EMSA) using
GST::LAG-1 and a previously described probe that binds LAG-1 through two
CSL-binding sites (Hwang et al.,
2007); arrowhead indicates free probe. Competitor DNA is from
enhA (see Fig.
2B). 2-CSL and 3-CSL indicate wild-type sites;
2-CSL* and 3-CSL* are ATGGGAA to
AAGGCAA and GTGGGAA to GAGGCAA mutations, respectively. (B) EMSA using
in vitro translated ELT-2 and a labeled probe from the pho-1
endodermal enhancer (Fukushige et al.,
2003). Competitor DNA is the same as in A. 2-GATA and
3-GATA are the wild-type sites; 2-GATA* and
3-GATA* are mutations from GATA to CATA. Note that
competition with the [2-GATA 3-GATA*] probe is
approximately fivefold less than with the [2-GATA* 3-GATA]
probe.